Brief: LifeMD Q2 Revenue USD 62.2 Million Vs. IBES Estimate USD 66.3 Million

LifeMD

05/08/2025 21:05

Overview

LifeMD Q2 revenue rises 23% yr/yr but misses analyst expectations, per LSEG data

Adjusted EBITDA for Q2 up 223%, yet misses consensus estimates, per LSEG data

Company fully repaid senior debt and launched new behavioral health services

Outlook

LifeMD sees Q3 revenue between $61 mln and $63 mln

Company expects Q3 telehealth revenue between $48 mln and $50 mln

LifeMD anticipates full-year revenue between $250 mln and $255 mln

Company forecasts full-year telehealth revenue between $195 mln and $200 mln

Result Drivers

TELEHEALTH GROWTH - Telehealth revenue increased 30% yr/yr, driven by new service offerings

PLATFORM DIVERSIFICATION - Nationwide launch of behavioral health services and acquisition of women's health practice

MEMBERSHIP ENHANCEMENT - Scaling of LifeMD+ membership program with expanded services

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$62.20 mln
$66.30 mln (7 Analysts)
Q2 Net Income
-$2.90 mln
Q2 Adjusted EBITDA
Miss
$7.10 mln
$7.84 mln (6 Analysts)
Q2 Gross Margin
88.0%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for LifeMD Inc is $14.00, about 11.8% above its August 4 closing price of $12.35

The stock recently traded at 72 times the next 12-month earnings vs. a P/E of 314 three months ago

Press Release: ID:nGNX4Wj655

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)